Literature DB >> 22641284

The importance of quality of life for patients living with myelodysplastic syndromes.

Mary Laudon Thomas1, Nicole Crisp, Karen Campbell.   

Abstract

Myelodysplastic syndromes (MDS) are a group of myeloid stem cell clonal disorders characterized by a wide variation in illness trajectory and potential treatment. The physical, functional, emotional, social, and spiritual well-being of individuals with MDS can be affected by both disease and treatment-related factors. As a result, the quality of life (QOL) in patients with MDS may vary throughout the course of the illness. To date, most research exploring QOL in patients with MDS has been conducted as part of clinical trials evaluating the effectiveness of a therapeutic intervention. Although data from those studies are useful, they do not fully address the issues critical to maintaining or maximizing QOL. Oncology nurses are in a key position to assist patients with MDS to maintain their QOL. Findings from comprehensive QOL assessments will guide nurses in providing relevant interventions and evaluating their outcomes. In this manner, oncology nurses can assist their patients to maximize QOL while living with this challenging illness.

Entities:  

Mesh:

Year:  2012        PMID: 22641284     DOI: 10.1188/12.CJON.S1.47-57

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  7 in total

1.  Quality of life in higher resolution: the next generation of comparative effectiveness research in malignant hematology.

Authors:  Thomas W LeBlanc; Amy P Abernethy
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 2.  Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Authors:  Myles Nickolich; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.

Authors:  Esther Natalie Oliva; Uwe Platzbecker; Guillermo Garcia-Manero; Ghulam J Mufti; Valeria Santini; Mikkael A Sekeres; Rami S Komrokji; Jeevan K Shetty; Derek Tang; Shien Guo; Weiqin Liao; George Zhang; Xianwei Ha; Rodrigo Ito; Jennifer Lord-Bessen; Jay T Backstrom; Pierre Fenaux
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

Review 4.  Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.

Authors:  Johannes M Giesinger; Giorgio La Nasa; Francesco Sparano; Matthias Angermeyer; Emanuela Morelli; Olga Mulas; Fabio Efficace; Giovanni Caocci
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-12-31

Review 5.  Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Authors:  Emanuela Morelli; Olga Mulas; Giovanni Caocci
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-12-31

Review 6.  Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes.

Authors:  Ioannis Koutsavlis
Journal:  Anemia       Date:  2016-04-19

7.  End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach.

Authors:  Mary-Joanne Verhoef; Ellen J M de Nijs; Claudia S Ootjers; Marta Fiocco; Anne J Fogteloo; Christian Heringhaus; Corrie A M Marijnen; Nanda Horeweg; Yvette M van der Linden
Journal:  Am J Hosp Palliat Care       Date:  2019-12-23       Impact factor: 2.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.